We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Polysome Screen Identifies Cancer Related MicroRNAs

By LabMedica International staff writers
Posted on 04 Sep 2018
An international research team has developed a polysome-based method for detecting microRNAs (miRNAs) that act to promote or sustain growth of malignant mesothelioma and other types of cancer.

MicroRNAs are short RNA molecules about 22 nucleotides in length. More...
Essentially, miRNAs specifically target certain messenger RNAs (mRNAs) to prevent them from coding for a specific protein. The expression of miRNAs in cancer has been widely studied and has allowed this activity to be classified as oncomir (also oncomiR) or oncosuppressor.

The dysregulation of oncomirs has been associated with specific cancer forming events such as malignant transformation and metastasis. Some oncomir genes are oncogenes, in that overexpression of the gene leads to cancerous growth. Other oncomir genes are tumor suppressors in a normal cell, so that under expression of the gene leads to cancerous growth.

In order to identify biologically active oncomirs, investigators at the National Institute of Molecular Genetics (Milan, Italy) and their collaborators in Italy and the United States developed a screen for miRNAs acting on the polysomes of malignant mesothelioma (MPM) cells. A polysome (or polyribosome) is a complex comprising an mRNA molecule and two or more ribosomes that act to translate mRNA instructions into polypeptides.

They investigators reported in the August 2, 2018, online edition of the journal Cancer Research that only a small percentage of expressed miRNAs physically associated with polysomes. On polysomes, they identified miRNAs already characterized in MPM, as well as novel ones like miR-24-3p, which acted as a pro-migratory miRNA in all cancer cells tested. They found that miR-24-3p positively regulated the activity of the enzyme Rho-GTP, a kinase involved in regulating the shape and movement of cells by acting on the cytoskeleton. In contrast, inhibition of miR-24-3p reduced growth in MPM cells.

Among the specific targets of miR-24-3p was cingulin, a tight junction protein that inhibited Rho-GTP activity. Overexpression of miR-24-3p was found to only partially inhibit cingulin mRNA but to completely eliminate cingulin protein, confirming its action via translational repression. This finding confirmed that miR-24-3p was an oncomir, and suggested that identification of polysome-associated miRNAs efficiently sorted out biologically active miRNAs from inactive ones.

“We have identified a novel approach for identifying relevant miRNA in cancer biology,” said senior author Dr. Stefano Biffo, professor of cell biology at the University of Milan (Italy) and group leader at the National Institute of Molecular Genetics. “By examining the polyribosomes where translation occurs, this "focused" search has allowed us to identify that miR-24-3p (a particular miRna) expression is relevant to cancer progression and metastasis.”

Related Links:
National Institute of Molecular Genetics
University of Milan


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Luteinizing Hormone Test
Luteinizing Hormone (LH) Rapid Test
New
Glucose Tolerance Test
NERL Trutol
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.